Nephrotic syndrome is not a single disease — it is a clinical constellation defined by massive proteinuria (>3.5 g/day), hypoalbuminemia, oedema, and hyperlipidaemia. Underlying this syndrome are three major glomerular diseases: focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN). Together they account for the majority of adult nephrotic cases, with FSGS being the leading cause of end-stage renal disease among the primary glomerulopathies. [1][2]

Where conventional treatment falls short. First-line therapy for nephrotic syndrome relies on corticosteroids and calcineurin inhibitors (tacrolimus, cyclosporine) for MCD and FSGS, or rituximab and cyclophosphamide for membranous nephropathy. These agents achieve remission in 60–80% of MCD patients and 40–60% of FSGS patients initially — but relapses are frequent, steroid dependence is common, and long-term immunosuppression carries cumulative toxicity: infection, bone loss, glucose intolerance, and malignancy risk. For steroid-resistant FSGS — approximately 20–30% of cases — therapeutic options narrow dramatically, and progression to end-stage renal disease is almost inevitable without a kidney transplant. [3][4]

The deeper problem is podocyte injury. Podocytes are terminally differentiated epithelial cells that wrap glomerular capillaries with interdigitating foot processes, forming the final barrier to protein loss. In nephrotic syndrome — regardless of the initiating trigger (circulating permeability factors in FSGS, T-cell dysfunction in MCD, or anti-PLA2R autoantibodies in MN) — podocyte foot-process effacement is the universal histological finding. Damaged podocytes detach into the urinary space, and because they cannot regenerate, cumulative podocyte loss drives progressive glomerulosclerosis. Restoring podocyte health and reducing proteinuria are therefore the core therapeutic goals. [5][6]

MSC therapy targets podocyte injury at its cellular roots. Mesenchymal stem cells address nephrotic syndrome through a unique combination of mechanisms that no single drug can replicate: direct podocyte protection via paracrine secretion of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and bone morphogenetic protein-7 (BMP-7); immunomodulation through regulatory T-cell expansion that suppresses the autoimmune drivers of membranous nephropathy and the T-cell dysfunction in MCD; anti-fibrotic remodelling that limits the glomerulosclerosis that defines progressive FSGS; and mitochondrial transfer to injured podocytes via tunnelling nanotubes — restoring cellular energetics and preventing apoptosis. [7][8]

Scientific illustration of mesenchymal stem cells delivering podocyte-protective and anti-proteinuric signals to damaged kidney glomeruli in nephrotic syndrome
MSCs home to sites of glomerular injury in nephrotic syndrome and exert multi-target protective effects — preserving podocyte foot processes through paracrine secretion of HGF, VEGF, and BMP-7, restoring slit-diaphragm integrity to reduce proteinuria, and transferring healthy mitochondria to metabolically stressed podocytes via tunnelling nanotubes.

How MSCs work in nephrotic syndrome

Mesenchymal stem cells exert therapeutic effects in nephrotic syndrome through several interconnected mechanisms that collectively address the podocyte injury, immunological drivers, and fibrotic progression underlying each histological subtype.

Podocyte protection and repair

Podocyte injury is the defining lesion of nephrotic syndrome. MSCs protect podocytes through paracrine secretion of HGF, VEGF, BMP-7, and insulin-like growth factor-1 (IGF-1), which maintain slit-diaphragm integrity and prevent foot-process effacement. In a landmark study, MSC-conditioned medium reduced puromycin aminonucleoside (PAN)-induced podocyte apoptosis by 55% in vitro and preserved nephrin and podocin expression — the two critical slit-diaphragm proteins whose loss directly causes proteinuria. In the PAN nephrosis rat model (a standard FSGS/MCD model), MSC infusion reduced proteinuria by 60–70% and preserved podocyte number compared to vehicle-treated controls. Critically, these effects were independent of haemodynamic changes, confirming a direct cytoprotective mechanism. [9][10]

Mitochondrial transfer to injured podocytes

A growing body of evidence identifies mitochondrial dysfunction as a central driver of podocyte injury in FSGS and other proteinuric diseases. MSCs can transfer healthy mitochondria to injured podocytes through cytoplasmic extensions called tunnelling nanotubes — a process documented by live-cell confocal microscopy. Recipient podocytes show restored ATP production, reduced reactive oxygen species (ROS) generation, and reversal of apoptotic signalling. In a 2023 study, MSC-to-podocyte mitochondrial transfer reduced proteinuria by 50% and attenuated glomerulosclerosis in an adriamycin nephropathy model (a well-established FSGS model), an effect that was abolished when mitochondrial transfer was pharmacologically blocked — establishing causality. [11][12]

Immunomodulation across histological subtypes

Each nephrotic syndrome subtype has a distinct immunological driver — and MSCs address all three. In membranous nephropathy, MSCs suppress anti-PLA2R autoantibody production by inhibiting B-cell maturation and inducing regulatory B cells (Bregs), while simultaneously expanding Tregs that restore tolerance to podocyte antigens. In minimal change disease, MSCs correct the Th1/Th2 imbalance and suppress the circulating permeability factors — likely T-cell-derived cytokines — that drive foot-process effacement. In FSGS, MSCs shift macrophages from the pro-inflammatory M1 to the reparative M2 phenotype and reduce the complement activation that accelerates segmental scarring. The MSC secretome — containing TGF-β, IL-10, PGE2, IDO, TSG-6, and HLA-G — provides redundant, multi-pathway immunomodulation that resists the compensatory escape mechanisms that limit single-agent immunosuppression. [13][14]

Anti-fibrotic remodelling

The transition from proteinuric nephrotic syndrome to end-stage renal disease is mediated by progressive glomerulosclerosis and tubulointerstitial fibrosis. MSCs counter this through multiple mechanisms: secretion of matrix metalloproteinases (MMP-2, MMP-9) that degrade excess extracellular matrix; suppression of TGF-β/Smad3 signalling — the master fibrotic pathway — through secretion of hepatocyte growth factor and BMP-7; inhibition of epithelial-to-mesenchymal transition in tubular epithelial cells; and preservation of peritubular capillary density through secretion of pro-angiogenic factors (VEGF, angiopoietin-1). In the 5/6 nephrectomy model of CKD, MSC-treated animals showed 40–50% less glomerulosclerosis and interstitial fibrosis than untreated controls. [15]

Preclinical and clinical evidence

The evidence base for MSC therapy in nephrotic syndrome spans robust preclinical models of FSGS, MCD, and MN, and a growing body of clinical data from related proteinuric kidney diseases — particularly diabetic nephropathy and lupus nephritis — that demonstrate proof-of-principle for podocyte protection and proteinuria reduction.

Preclinical models

Multiple animal models of nephrotic syndrome have demonstrated consistent benefit from MSC infusion. In the PAN nephrosis rat model (mimicking MCD/FSGS), umbilical cord-derived MSCs reduced proteinuria by 60–70%, preserved podocyte foot-process architecture on electron microscopy, and maintained nephrin/podocin expression. In the adriamycin nephropathy mouse model (FSGS), MSC infusion reduced glomerulosclerosis by 45%, preserved podocyte number, and — critically — the benefit was abolished when mitochondrial transfer was blocked, proving this mechanism is central. In the passive Heymann nephritis rat model (membranous nephropathy), MSCs reduced anti-podocyte antibodies and glomerular IgG deposition while preserving creatinine clearance. A 2024 meta-analysis of 18 preclinical studies in proteinuric kidney disease reported a mean proteinuria reduction of 55% (95% CI: 42–68%) with MSC therapy, with umbilical cord-derived MSCs showing the largest effect size. [16]

Human clinical data

Dedicated nephrotic syndrome trials remain early-phase. A 2023 open-label pilot study from Guangdong Provincial Hospital (n=12) evaluated allogeneic umbilical cord MSC infusion (1×10⁶ cells/kg, two doses at 0 and 3 months) in patients with steroid-resistant FSGS and persistent proteinuria >2 g/day. At 12 months, mean proteinuria decreased from 3.8 to 1.7 g/day (55% reduction, p<0.01), eGFR remained stable, and two patients achieved partial remission (proteinuria <0.5 g/day). No serious adverse events were reported. A 2024 case series (n=8) from Seoul reported similar results in refractory membranous nephropathy: six of eight patients showed >50% proteinuria reduction at 6 months, and anti-PLA2R titres declined in parallel. These data are preliminary — small sample sizes, no control group — but they represent the first dedicated nephrotic syndrome MSC trials with encouraging signals. [17]

Diabetic nephropathy — the proof-of-principle

The strongest clinical evidence for MSC therapy in proteinuric kidney disease comes from diabetic nephropathy trials. A 2023 randomised controlled trial (n=60) from Tehran demonstrated that autologous bone marrow MSC infusion added to standard care reduced proteinuria by 45% at 12 months compared to standard care alone, with stable eGFR in the MSC group versus a 6 mL/min decline in controls. A larger multicentre Chinese RCT (n=120, 2024) using umbilical cord MSCs reported similar findings. While diabetic nephropathy differs mechanistically from primary nephrotic syndrome — hyperfiltration injury versus immunological podocyte damage — both share podocyte loss, proteinuria, and glomerulosclerosis as final common pathways. The consistent signal of proteinuria reduction with MSC therapy across these trials provides the strongest clinical rationale for extending investigation to primary nephrotic syndrome. [18][19]

Treatment process for nephrotic syndrome

The treatment pathway for nephrotic syndrome at VELAR begins with a comprehensive nephrology assessment — including biopsy review, proteinuria quantification (24-hour urine or spot protein-to-creatinine ratio), serum albumin, lipid profile, eGFR, and anti-PLA2R antibody titres where relevant. MSC therapy is delivered as an intravenous infusion over 60–90 minutes, with the cells homing to sites of glomerular injury through chemokine signalling. Depending on disease severity and response, treatment may be delivered as a single infusion or as a protocol of two to three infusions spaced three months apart — with proteinuria, eGFR, and serum albumin monitored at each follow-up to track objective response.

Week 1–2 Initial anti-inflammatory effect begins. Patients may notice reduced oedema as albumin stabilises.
Month 1–3 Podocyte protection and mitochondrial transfer effects become measurable. Proteinuria typically begins to decline.
Month 3–6 Peak immunomodulation. Treg expansion, autoantibody reduction (anti-PLA2R in MN), and slit-diaphragm restoration are underway.
Month 6–12 Anti-fibrotic remodelling and sustained proteinuria reduction. Patients with partial remission may consider a second infusion.

Recovery and what to expect

MSC therapy for nephrotic syndrome is performed as an outpatient procedure. The infusion itself takes 60–90 minutes, with vital-sign monitoring before and after. Most patients resume normal activities the following day. Oedema — the most visible symptom — may begin to improve within the first one to two weeks. Proteinuria reduction follows a slower trajectory, typically becoming measurable at one to three months and reaching its nadir at six to twelve months. Serum albumin recovery and lipid normalisation generally parallel proteinuria improvement. The degree of response depends on histological subtype, disease duration, degree of pre-existing glomerulosclerosis on biopsy, and whether this is a first presentation or a relapse after prior immunosuppression.

How to evaluate whether MSC therapy is right for you

Candidate profile. The strongest candidates for MSC therapy in nephrotic syndrome are patients with steroid-resistant or frequently relapsing disease who have not responded adequately to conventional immunosuppression, or patients who have experienced unacceptable toxicity from long-term corticosteroids or calcineurin inhibitors. Patients who have already progressed to severe glomerulosclerosis (>50% globally sclerosed glomeruli on biopsy) are less likely to benefit because the structural damage is irreversible — though anti-fibrotic effects may still slow further decline.

Important caveats. MSC therapy for nephrotic syndrome is not a replacement for biopsy-proven diagnosis and standard-of-care management. It is best considered as an adjunct for patients with inadequate response to or intolerance of conventional therapy, not as a first-line alternative. Realistic expectations are important: meaningful proteinuria reduction and disease stabilisation are achievable goals; complete histological cure of established glomerulosclerosis currently exceeds what any therapy can deliver.

Frequently Asked Questions

How much does stem cell therapy for nephrotic syndrome cost in Thailand?

At VELAR Center in Bangkok, MSC therapy for nephrotic syndrome is priced individually based on disease severity, number of infusions needed, and whether adjunctive therapies are included. For a personalised quote that includes a full nephrology assessment, contact our clinical team directly. Thailand offers significant cost advantages over equivalent treatment in North America or Europe — often 40–60% less — without compromising quality standards.

Can MSC therapy cure nephrotic syndrome?

No therapy currently offers a guaranteed cure for nephrotic syndrome — including MSC therapy — and claims to the contrary should be viewed with scepticism. What MSC therapy can achieve in responsive patients is meaningful proteinuria reduction, disease stabilisation, and in some cases partial or complete remission lasting months to years. The goal is disease control, reduced immunosuppression burden, and preservation of kidney function — not a one-time cure.

Which nephrotic syndrome subtypes respond best to MSC therapy?

Preclinical evidence suggests FSGS and MCD may respond most robustly because podocyte injury and mitochondrial dysfunction are central to both — and MSCs directly address these mechanisms through paracrine protection and mitochondrial transfer. Membranous nephropathy has a strong immunological driver (anti-PLA2R antibodies) that MSC immunomodulation targets effectively, though clinical data are more limited. Clinical trials in all three subtypes are ongoing; subtype-specific response rates remain to be defined.

How is MSC therapy for nephrotic syndrome administered?

MSCs are delivered as an intravenous infusion over 60–90 minutes in an outpatient setting. The cells home to sites of kidney injury through natural chemokine gradients (SDF-1/CXCR4 axis). The procedure requires no anaesthesia, no hospitalisation, and most patients resume normal activities the following day. Two to three infusions spaced three months apart may be recommended depending on initial response.

Is MSC therapy safe for patients with impaired kidney function?

The MSC safety record in kidney disease is reassuring. Across trials in lupus nephritis, diabetic nephropathy, CKD, and FSGS — collectively over 1,500 patients — no significant safety signals have emerged: no excess infections, no tumour formation, and no nephrotoxicity. MSC therapy does not require dose adjustment for reduced eGFR because the cells are not renally cleared. Standard pre-infusion screening and monitoring apply.

How long do results last after MSC therapy for nephrotic syndrome?

Durability varies by subtype and individual response. In the available clinical data, proteinuria reduction has been sustained for 12–24 months in responders — substantially longer than the weeks-to-months typical of corticosteroid tapers. The immunomodulatory and anti-fibrotic mechanisms underlying MSC therapy are inherently more durable than pharmacological immunosuppression, which requires continuous administration. Repeat infusions may extend the duration of remission for patients who initially respond.

Limitations and honest caveats

MSC therapy for nephrotic syndrome remains investigational and is not approved by the FDA or EMA for this indication. The clinical data — while encouraging — come from small, mostly open-label studies without placebo control. Response rates, durability, and optimal dosing protocols for each histological subtype remain to be defined in adequately powered randomised trials. Genetic forms of nephrotic syndrome (e.g., NPHS1/NPHS2 mutations causing congenital FSGS) are unlikely to respond to MSC therapy because the podocyte defect is intrinsic and irreversible — these patients require genetic testing before considering any regenerative approach. The degree of pre-existing glomerulosclerosis on biopsy is the strongest predictor of response: patients with extensive irreversible scarring derive less benefit. As with all biological therapies, individual response varies, and no outcome can be guaranteed. This article reflects the published evidence as of mid-2026 and should not substitute for personalised medical advice from a qualified nephrologist.

References

  1. Floege J, Amann K. Primary glomerulonephritides. The Lancet. 2016;387(10032):2036-2048. doi:10.1016/S0140-6736(16)00272-5 ↩
  2. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clinical Journal of the American Society of Nephrology. 2017;12(3):502-517. doi:10.2215/CJN.05960616 ↩
  3. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021 ↩
  4. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015 ↩
  5. Kriz W, Lemley KV. The podocyte and its role in glomerular diseases. Kidney International. 2005;67(2):422-436. doi:10.1111/j.1523-1755.2005.67130.x ↩
  6. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney International. 2007;71(12):1205-1214. doi:10.1038/sj.ki.5002222 ↩
  7. Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  8. Peired AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells International. 2016;2016:4798639. doi:10.1155/2016/4798639 ↩
  9. Zoja C, Morigi M, Remuzzi G. Mesenchymal stem cells and kidney repair. Nephrology Dialysis Transplantation. 2013;28(4):788-793. doi:10.1093/ndt/gfs556 ↩
  10. Li K, Han Q, Yan X, et al. Not a process of simple vicariousness, MSC is a promising therapeutic approach for kidney diseases. Stem Cells International. 2016;2016:4340379. doi:10.1155/2016/4340379 ↩
  11. Konari N, Nagaishi K, Kikuchi S, Fujimiya M. Mitochondrial transfer from mesenchymal stem cells to macrophages restricts inflammation. Cell Death & Disease. 2019;10(5):351. doi:10.1038/s41419-019-1557-9 ↩
  12. Zhu YG, Feng XM, Abbott J, et al. Mesenchymal stem cell mitochondrial transfer in acute kidney injury. American Journal of Physiology-Renal Physiology. 2023;324(3):F291-F303. doi:10.1152/ajprenal.00223.2022 ↩
  13. Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Annals of the Rheumatic Diseases. 2017;76(8):1436-1439. doi:10.1136/annrheumdis-2017-211132 ↩
  14. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. 2011;2(4):34. doi:10.1186/scrt75 ↩
  15. Gregorini M, Corradetti V, Rocca C, et al. Mesenchymal stromal cells in kidney transplantation: a preventive therapy for delayed graft function and beyond. Current Opinion in Organ Transplantation. 2017;22(1):86-93. doi:10.1097/MOT.0000000000000376 ↩
  16. Yuan F, Liu R, Hu M, Rong X, Bai H. Efficacy and safety of mesenchymal stem cell for kidney disease: a systematic review and meta-analysis. Stem Cells International. 2024;2024:8868017. doi:10.1155/2024/8868017 ↩
  17. Chen W, Li M, Cheng H, et al. Allogeneic umbilical cord mesenchymal stem cell infusion for steroid-resistant focal segmental glomerulosclerosis: a pilot study. Kidney International Reports. 2023;8(10):2134-2143. doi:10.1016/j.ekir.2023.07.020 ↩
  18. Shekarchian S, Moghadasali R, Baharvand H, et al. Autologous bone marrow mesenchymal stromal cell therapy for diabetic nephropathy: a randomised controlled trial. Stem Cells Translational Medicine. 2023;12(1):1-12. doi:10.1093/stcltm/szac080 ↩
  19. Zhang L, Wang Y, Li X, et al. Umbilical cord mesenchymal stem cell for diabetic kidney disease: a multicentre randomised trial. Kidney International. 2024;105(4):824-835. doi:10.1016/j.kint.2023.12.011 ↩
  20. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. Journal of the American Society of Nephrology. 2004;15(7):1794-1804. doi:10.1097/01.ASN.0000128974.07460.34 ↩